Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol-Funded Africa HIV/AIDS Research Program Will Treat Subjects For Life

Executive Summary

Patients enrolled in clinical trials supported by Bristol-Myers Squibb's "Secure the Future" international HIV/AIDS research and community outreach program will have access to treatment for life.

You may also be interested in...



Novartis Leprosy Drug Lamprene To Be Distributed By HHS

HHS will be the sole distributor for Novartis' leprosy drug Lamprene (clofazimine) beginning this summer

Novartis Leprosy Drug Lamprene To Be Distributed By HHS

HHS will be the sole distributor for Novartis' leprosy drug Lamprene (clofazimine) beginning this summer

Bristol HIV Price Cut Includes Pledge Not To Enforce Patent Rights In Africa

Bristol-Myers Squibb's HIV drug price cut for sub-Saharan African countries includes a pledge not to enforce patent rights for Videx (didanosine) and Zerit (stavudine).

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel